The effect of high-flow arteriovenous fistulas on systemic haemodynamics and brain oxygenation.
Arteriovenous fistula
Brain oximetry
Effective cardiac output
High-output heart failure
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
01
03
2021
received:
21
10
2020
accepted:
05
03
2021
pubmed:
24
3
2021
medline:
3
7
2021
entrez:
23
3
2021
Statut:
ppublish
Résumé
High-flow arteriovenous fistula (AVF) for haemodialysis leads to profound haemodynamic changes and sometimes to heart failure (HF). Cardiac output (CO) is divided between the AVF and body tissues. The term effective CO (COef) represents the difference between CO and AVF flow volume (Qa) and better characterizes the altered haemodynamics that may result in organ hypoxia. We investigated the effects of Qa reduction on systemic haemodynamics and on brain oxygenation. This is a single-centre interventional study. Twenty-six patients on chronic haemodialysis with high Qa (>1500 mL/min) were indicated for surgical Qa reduction for HF symptoms and/or signs of structural heart disease on echocardiography. The included patients underwent three sets of examinations: at 4 months and then 2 days prior and 6 weeks post-surgical procedure. Clinical status, echocardiographical haemodynamic assessment, Qa, and brain oximetry were recorded. All parameters remained stable from selection to inclusion. After the procedure, Qa decreased from 3.0 ± 1.4 to 1.3 ± 0.5 L/min, P < 0.00001, CO from 7.8 ± 1.9 to 6.6 ± 1.5 L/min, P = 0.0002, but COef increased from 4.6 ± 1.4 to 5.3 ± 1.4 L/min, P = 0.036. Brain tissue oxygen saturation increased from 56 ± 11% to 60 ± 9%, P = 0.001. Qa reduction led to increased COef. This was explained by a decreased proportion of CO running through the AVF in patients with Qa > 2.0 L/min. These observations were mirrored by higher brain oxygenation and might explain HF symptoms and improved haemodynamics even in asymptomatic high Qa patients.
Identifiants
pubmed: 33755355
doi: 10.1002/ehf2.13305
pmc: PMC8120398
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2165-2171Informations de copyright
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Hypertension. 2004 Jan;43(1):101-8
pubmed: 14638623
Physiol Res. 2020 Dec 22;69(6):1013-1028
pubmed: 33129242
ESC Heart Fail. 2021 Jun;8(3):2165-2171
pubmed: 33755355
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Blood Purif. 2011;31(1-3):113-20
pubmed: 21228578
Nephron. 2018;139(2):113-119
pubmed: 29439251
Eur Heart J. 2017 Jun 21;38(24):1913-1923
pubmed: 28329100
Kidney Blood Press Res. 2017;42(1):165-176
pubmed: 28395286
J Biopharm Stat. 1999 Aug;9(3):417-38
pubmed: 10473029
Circulation. 2019 Jun 18;139(25):2809-2818
pubmed: 31045455
Congest Heart Fail. 2013 Jul-Aug;19(4):E40-5
pubmed: 23615021
J Vasc Access. 2021 Jan;22(1):90-93
pubmed: 32489138
Semin Dial. 2018 Jan;31(1):15-20
pubmed: 28990213
J Anesth. 2019 Jun;33(3):478-481
pubmed: 31062096
PLoS One. 2015 Feb 23;10(2):e0117474
pubmed: 25706868
Am J Kidney Dis. 2002 Oct;40(4):753-9
pubmed: 12324910
J Vasc Access. 2018 Jan;19(1):3-11
pubmed: 29192719
Clin J Am Soc Nephrol. 2016 Apr 7;11(4):549-51
pubmed: 26936947
PLoS One. 2018 Jun 25;13(6):e0199366
pubmed: 29940017
Physiol Res. 2019 Aug 29;68(4):651-658
pubmed: 31177793
Nephron Clin Pract. 2014;128(1-2):57-60
pubmed: 25342499
J Vasc Access. 2017 Jan 18;18(1):47-51
pubmed: 27886367
Am J Kidney Dis. 2013 Apr;61(4):612-22
pubmed: 23164943
J Am Coll Cardiol. 2016 Aug 2;68(5):473-482
pubmed: 27470455
J Am Coll Cardiol. 2014 Apr 8;63(13):1246-1252
pubmed: 24530671
J Vasc Access. 2015;16 Suppl 9:S96-101
pubmed: 25751561
QJM. 2009 Apr;102(4):235-41
pubmed: 18990720
Sci Rep. 2019 Jul 24;9(1):10708
pubmed: 31341241